MAPT and Alzheimer disease: Finally, using Aβ PET as a proxy of disease progression, we modelled the trajectory of CSF p‐tau235 in preclinical AD, situating the emergence of abnormal CSF p‐tau235 values after CSF p‐tau231 and p‐tau217 and before CSF p‐tau181 and total tau.